NasdaqCM - Nasdaq Real Time Price USD

Immix Biopharma, Inc. (IMMX)

2.3100 +0.0600 (+2.67%)
At close: 4:00 PM EDT
2.3600 +0.05 (+2.16%)
After hours: 4:23 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
19,210.4920
16,141.1130
8,218.9480
1,352.0140
453.8520
--
Operating Income
-19,210.4920
-16,141.1130
-8,218.9480
-1,352.0140
-453.8520
--
Net Non Operating Interest Income Expense
812.0220
572.0060
-0.4970
-179.8530
-101.9760
--
Other Income Expense
--
--
--
-22,845.9990
-574.4880
0.2240
Pretax Income
-18,398.4700
-15,569.1070
-8,219.4450
-24,377.8660
-1,130.3160
--
Tax Provision
30.0840
26.4150
10.2680
6.0130
17.5470
--
Net Income Common Stockholders
-18,205.3750
-15,426.0480
-8,229.7130
-24,383.8790
-1,147.8630
--
Diluted NI Available to Com Stockholders
-18,205.3750
-15,426.0480
-8,229.7130
-24,383.8790
-1,147.8630
--
Basic EPS
-0.93
--
-0.59
-6.64
-0.13
-0.12
Diluted EPS
-0.93
--
-0.59
-6.64
-0.13
-0.12
Basic Average Shares
19,726.3860
--
13,887.3090
3,672.6110
8,774.8520
8,442.5520
Diluted Average Shares
19,726.3860
--
13,887.3090
3,672.6110
8,774.8520
8,442.5520
Total Operating Income as Reported
-19,210.4920
-16,141.1130
-8,218.9480
-1,352.0140
-453.8520
--
Total Expenses
19,210.4920
16,141.1130
8,218.9480
1,352.0140
453.8520
--
Net Income from Continuing & Discontinued Operation
-18,205.3750
-15,426.0480
-8,229.7130
-24,383.8790
-1,147.8630
--
Normalized Income
-18,205.3750
-15,426.0480
-8,229.7130
-7,706.2997
-728.1130
--
Interest Income
812.0220
572.0060
--
--
--
--
Interest Expense
--
--
0.4970
179.8530
101.9760
--
Net Interest Income
812.0220
572.0060
-0.4970
-179.8530
-101.9760
--
EBIT
-18,638.4860
-15,569.1070
-8,218.9480
-24,198.0130
-1,028.3400
--
EBITDA
-18,609.6730
-15,563.6390
-8,216.8130
-24,195.5450
-1,026.0190
--
Reconciled Depreciation
28.8130
5.4680
2.1350
2.4680
2.3210
--
Net Income from Continuing Operation Net Minority Interest
-18,205.3750
-15,426.0480
-8,229.7130
-24,383.8790
-1,147.8630
--
Total Unusual Items Excluding Goodwill
--
--
--
-22,845.9990
-575.0000
--
Total Unusual Items
--
--
--
-22,845.9990
-575.0000
--
Normalized EBITDA
-18,609.6730
-15,563.6390
-8,216.8130
-1,349.5460
-451.0190
--
Tax Rate for Calcs
0.0004
0.0002
0.0002
0.0003
0.0003
--
Tax Effect of Unusual Items
--
--
--
-6,168.4197
-155.2500
--
12/31/2019 - 12/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CLRB Cellectar Biosciences, Inc.
2.9600
-4.82%
 
KTTA Pasithea Therapeutics Corp.
6.30
-2.32%
 
NERV Minerva Neurosciences, Inc.
2.4400
0.00%
 
NVCT Nuvectis Pharma, Inc.
6.58
+5.96%
 
ENSC Ensysce Biosciences, Inc.
0.5750
+0.52%
 
PASG Passage Bio, Inc.
1.1900
+5.31%
 
TSHA Taysha Gene Therapies, Inc.
3.2500
+0.31%
 
PGEN Precigen, Inc.
1.3650
+0.37%
 
NRSN NeuroSense Therapeutics Ltd.
1.0900
+2.83%
 
MAIA MAIA Biotechnology, Inc.
4.1100
+9.89%